ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.
Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Clone IM19 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects WW domain-containing transcription regulator protein (TAZ). It targets an epitope within 21 amino acids from the coiled-coil region from the C-terminal half.
KLH-conjugated linear peptide corresponding to 21 amino acids from the coiled-coil region from the C-terminal half.
Quality Control Testing
Evaluated by Western Blotting in NIH3T3 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected TAZ in NIH3T3 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected TAZ in U2OS cell lysate.
Affinity Binding Assay: A representative lot of this antibody bound WWTR1 peptides with a KD of 1.0 x 10-12 in an affinity binding assay.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected TAZ in Hela cell line, A431 cell line, HepG2 and NIH3T3 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected TAZ in human kidney tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-TAZ, clone 1M19 ZooMAb®, Cat. No. ZRB1260, is a recombinant Rabbit monoclonal antibody that specifically targets TAZ and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.
WW domain-containing transcription regulator protein 1 (UniProt: Q9GZV5; also known as Transcriptional coactivator with PDZ-binding motif, TAZ) is encoded by the WWTR1 (also known as TAZ) gene (Gene ID: 25937) in human. TAZ is an oncogenic transcriptional activator that acts as a downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. It is shown to be highly expressed in kidney, heart, placenta, lung and in the thyroid tissue. It concentrates along specific portions of the plasma membrane and accumulates in punctate nuclear bodies. It binds to transcription factors via its WW domain. The ability of TAZ to regulate gene transcription is very tightly regulated through the phosphorylation-dependent binding of 14-3-3 protein. Its phosphorylation by LATS2 results in creation of 14-3-3 binding sites, retention in the cytoplasm, and functional inactivation. Phosphorylation also results in the inhibition of transcriptional coactivation through Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ). Its nuclear retention is achieved by Mediator of RNA polymerase II transcription subunit 15 (MED15). TAZ is shown to be involved in non-small-cell lung cancer and its higher expression levels are observed in breast cancer and in breast cancer stem cells. It also regulates embryonic stem-cell self-renewal and promotes cell proliferation and epithelial-mesenchymal transition. Loss of TAZ leads to inhibition of TGF signalling and differentiation into a neuroectoderm lineage. In the absence of TAZ, Smad2/3-4 complexes fail to accumulate in the nucleus and activate transcription. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Varelas, X., et al. (2008). Nat. Cell Biol. 10(7); 837-848).
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.